125 related articles for article (PubMed ID: 38394851)
1. Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectives.
Liu J; Yuan Q; Guo H; Guan H; Hong Z; Shang D
Biomed Pharmacother; 2024 Apr; 173():116310. PubMed ID: 38394851
[TBL] [Abstract][Full Text] [Related]
2. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled trials.
Xu HB; Huang F; Su R; Shen FM; Lv QZ
Eur J Clin Pharmacol; 2015 May; 71(5):589-601. PubMed ID: 25795200
[TBL] [Abstract][Full Text] [Related]
4. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
5. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
Argyriou AA; Velasco R; Briani C; Cavaletti G; Bruna J; Alberti P; Cacciavillani M; Lonardi S; Santos C; Cortinovis D; Cazzaniga M; Kalofonos HP
Ann Oncol; 2012 Dec; 23(12):3116-3122. PubMed ID: 22865779
[TBL] [Abstract][Full Text] [Related]
7. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.
Yu J; Gao Y; Chen L; Wu D; Shen Q; Zhao Z; Liu W; Yang H; Zhang Q; Wang X; Hu P; Zheng Z; Wang X; Liu H; Xu Z; Yan Z; Wu Y; Jin M; Zhang Q; Liu X; Zhu K; Shou C
JAMA Netw Open; 2022 Feb; 5(2):e220426. PubMed ID: 35226081
[TBL] [Abstract][Full Text] [Related]
8. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
9. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
[TBL] [Abstract][Full Text] [Related]
10. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
Lubner SJ; Loconte NK; Holen KD; Schelman W; Thomas JP; Jumonville A; Eickhoff JC; Seo S; Mulkerin DL
Clin Colorectal Cancer; 2010 Jul; 9(3):157-61. PubMed ID: 20643620
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
[TBL] [Abstract][Full Text] [Related]
15. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
16. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
Wu Y; Wei ZW; He YL; Schwarz RE; Smith DD; Xia GK; Zhang CH
World J Gastroenterol; 2013 Jun; 19(21):3309-15. PubMed ID: 23745033
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
20. [Progress in chemotherapy for advanced gastric cancer].
Xu RH; Teng KY
Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]